Akèy › Leksemi mieloïd egi › Colorado › Denver
Etid klinik pou Leksemi mieloïd egi nan Denver, CO
12 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Denver (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- AdventHealth Porter, Denver
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Ap rekriteFaz 3
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Ap rekriteFaz 1
- Colorado Blood Cancer Institute, Denver
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Colorado Blood Cancer Institute, Denver
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Colorado Blood Cancer Institute, Denver
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- Colorado Blood Cancer Institute, Denver
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Ap rekriteVolontè an sante akeyi
- University of Colorado Denver I Anschutz Medical Campus, Denver
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Ap rekriteFaz 1
- Colorado Blood Cancer Institute, Denver
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Baldwin Park, CA40 etid
- Seattle, WA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA30 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Denver
- Kansè Metastatik29 etid
- Kansè nan tete28 etid
- Myelom Miltip27 etid
- Kansè Poumon ki pa ti selil27 etid
- Kansè kolorektal23 etid
- Kansè pwostat19 etid
- Melanom19 etid
- Kansè (tout kalite)18 etid
- Kansè ovè16 etid
- Kansè poumon16 etid
- Kansè Endomèt15 etid
- Limfòm Non-Hodgkin14 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.